Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Cantargia AB (publ) is a Sweden-based biotechnology company specializing in the development of antibody therapeutics for cancer treatment. Its primary focus is on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a cell-surface receptor on malignant stem cells, to eradicate leukemia and other serious cancers. The lead product candidate, CAN04 (nadunolimab), addresses non-small cell lung cancer and pancreatic cancer, while the CAN10 project diversifies the portfolio into complementary disease segments. Headquartered in Lund with 23 employees, Cantargia AB operates in the healthcare sector, particularly biotechnology and medical research, without current revenue generation as it advances clinical programs. Incorporated in 2009 and public since 2015, the company holds a market capitalization around SEK 692 million, reflecting its role in innovative oncology therapies amid high research and development demands. Leadership includes CEO Göran Forsberg and a team of experienced executives and directors driving antibody-based innovations for life-threatening diseases.
kr 0.17
kr 0.00 (-0.36%)
EOD Jun 23, 2026 · Twelve Data
Margins and capital returns are both well above average: 48.75% operating margin, ROIC at 80.79%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Even for strong businesses, today's 0x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
0.3x earnings, 0.3x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 317M
Net Income (TTM)
kr 161M
▲ +190.9% YoY
Op. Margin
51.15%
ROIC
80.79%
▲ +174.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 158M
▲ +192.0% YoY
Op. Cash Flow (TTM)
kr 168M
▲ +194.5% YoY
Net Debt
-kr 282M
Net Cash Position
Cash & Equiv.
kr 282M
Continue Research
At a P/E of 0.3 and a price-to-free-cash-flow of 0.3, Cantargia AB (publ) (CANTA.XSTO) trades below a two-stage DCF intrinsic value of about SEK 14.55 per share, so at SEK 0.17 the stock looks undervalued (8,659.1% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cantargia AB (publ) scores 54/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 14.55 per share for CANTA.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 10.91. At today's SEK 0.17, that puts the stock about 8,659.1% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Cantargia AB (publ) scores 54 out of 100 on Intrinsiqq's quality score, passing 4 of 5 checks, which makes it a mixed business on these measures. Recent fundamentals include a 51.1% operating margin and a 80.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CANTA.XSTO currently trades below its estimated intrinsic value and scores 54/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.